Tasquinimod Purity Assessment via Decomposition Product Limiting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compositions containing tasquinimod lack effective methods for assessing purity and stability, particularly in the presence of degradation products, which is crucial for ensuring product quality and safety before distribution.
Innovation Solution
A pharmaceutical composition comprising tasquinimod or its pharmaceutically acceptable salt, along with specific excipients, and a method for assessing the product's suitability by determining the amount of tasquinimod decomposition products, ensuring not more than 5% w/w of these products relative to tasquinimod, thereby evaluating the product's stability and suitability for distribution.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tasquinimod is incorporated into a pharmaceutical composition, then the product can be used for therapeutic purposes, but degradation products may form compromising product quality and safety
Solution Approach 1:
The patent performs stability testing and degradation product assessment before the pharmaceutical product is distributed or used. By conducting purity assessment methods in advance, the invention identifies and quantifies degradation products prior to therapeutic use, ensuring product quality requirements are met while preventing harmful degradation compounds from reaching patients.
2Manufacturing precision
If purity assessment methods are developed for tasquinimod pharmaceutical products, then product quality can be ensured, but the complexity of the assessment process increases
Solution Approach 1:
The patent employs chromatographic separation techniques as an intermediary method to resolve the complex mixture of tasquinimod and its degradation products. By using chromatography columns and mobile phases as mediators, the invention separates and isolates individual components, enabling accurate quantification of degradation products without requiring direct analysis of the complex pharmaceutical formulation.
Data Source
AI summary
A pharmaceutical composition containing tasquinimod or a pharmaceutically salt of tasquinimod, a method for assessment thereof and a process for its manufacture. The use in therapy of a pharmaceutical composition containing tasquinimod or a pharmaceutically acceptable salt of tasquinimod. The compound 3,3′-methylenebis(4-hydroxy-5-methoxy-1-methylquinoline-2(1H)-one) and its use in a method for assessing a pharmaceutical composition containing tasquinimod or a pharmaceutically acceptable salt of tasquinimod.